GT Biopharma Book Value Per Share vs. Price To Book
| GTBP Stock | USD 2.74 0.08 2.84% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 5.55011136 | Current Value 5.27 | Quarterly Volatility 36 K |
For GT Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of GT Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well GT Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between GT Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of GT Biopharma over time as well as its relative position and ranking within its peers.
GTBP |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.39) | Return On Assets (0.61) | Return On Equity (1.31) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
GT Biopharma Price To Book vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining GT Biopharma's current stock value. Our valuation model uses many indicators to compare GT Biopharma value to that of its competitors to determine the firm's financial worth. GT Biopharma is rated # 3 in book value per share category among its peers. It is rated # 4 in price to book category among its peers fabricating about 0.55 of Price To Book per Book Value Per Share. The ratio of Book Value Per Share to Price To Book for GT Biopharma is roughly 1.82 . At this time, GT Biopharma's Book Value Per Share is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value GT Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.GTBP Price To Book vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
GT Biopharma |
| = | 5.41 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
GT Biopharma |
| = | 2.97 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
GTBP Price To Book Comparison
GT Biopharma is currently under evaluation in price to book category among its peers.
GT Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in GT Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, GT Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of GT Biopharma's change in net profit over the period of time. It can combine multiple indicators of GT Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.1 K | -1.2 K | |
| Operating Income | -13.6 M | -14.3 M | |
| Income Before Tax | -7.6 M | -8 M | |
| Total Other Income Expense Net | 6 M | 6.3 M | |
| Net Loss | -7.6 M | -8 M | |
| Income Tax Expense | -13.6 K | -14.3 K | |
| Net Loss | -52.2 M | -54.8 M | |
| Net Loss | -10.2 M | -10.7 M | |
| Net Interest Income | 520 K | 546 K | |
| Interest Income | 741 K | 778 K | |
| Non Operating Income Net Other | 16.7 M | 14.8 M | |
| Change To Netincome | 39.6 M | 64.7 M | |
| Net Loss | (5.64) | (5.92) | |
| Income Quality | 1.17 | 1.22 | |
| Net Income Per E B T | 0.88 | 0.75 |
GTBP Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on GT Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of GT Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the GT Biopharma's important profitability drivers and their relationship over time.
Use GT Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.GT Biopharma Pair Trading
GT Biopharma Pair Trading Analysis
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your GT Biopharma position
In addition to having GT Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Synthetics Thematic Idea Now
Synthetics
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.